Ayretrade Inc (SUMM) 0.0610 $SUMM Summit Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ayretrade Inc (SUMM) 0.0610 $SUMM

Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
GlobeNewswire - Tue Aug 09, 6:01AM CDT
-- New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patients
SMMT: 6.78 (+0.03)

Summit Therapeutics to Present at Canaccord Genuity Growth Conference
GlobeNewswire - Fri Aug 05, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Erik Ostrowski, Chief Financial Officer, will present at the Canaccord Genuity Growth Conference, 11 August 2016 at 1:30pm EDT in Boston.
SMMT: 6.78 (+0.03)

First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, today announces that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid (formerly SMT C1100) in patients with DMD. Ezutromid dosing is expected to follow a screening period of up to 28 days.
SMMT: 6.78 (+0.03)

Summit Therapeutics to Host Utrophin R&D Day 15 June 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit's management on 15 June 2016 in New York City.
SMMT: 6.78 (+0.03)

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and C. difficile infection ('CDI', today reports its financial results for the first quarter ended 30 April 2016.
SMMT: 6.78 (+0.03)

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
GlobeNewswire - Tue May 31, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016.
SMMT: 6.78 (+0.03)

Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
GlobeNewswire - Mon May 23, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole's preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.
SMMT: 6.78 (+0.03)

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Tue May 10, 6:07AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and C. difficile infection ('CDI', today reports its financial results for the fourth quarter and fiscal year ended 31 January 2016.
SMMT: 6.78 (+0.03)

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Fri May 06, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2016 on Tuesday, 10 May 2015.
SMMT: 6.78 (+0.03)

Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection ('CDI', announces the strengthening of the intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States Patent and Trademark Office.
SMMT: 6.78 (+0.03)

Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
GlobeNewswire - Tue Apr 26, 6:02AM CDT
-- Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
SMMT: 6.78 (+0.03)

Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces the presentation today of major findings from the Phase 2 CoDIFy trial highlighting the potential of ridinilazole in the treatment of CDI at the 26 European Congress of Clinical Microbiology and Infectious Diseases ('ECCMID'. These findings include a markedly reduced recurrence rate and a statistically superior rate of sustained clinical response ('SCR' in patients with CDI receiving ridinilazole compared with those receiving the standard of care, vancomycin. Ridinilazole is a novel class antibiotic with the potential for broad use across the CDI disease spectrum.
SMMT: 6.78 (+0.03)

Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at Needham & Company's 15 Annual Healthcare Conference, 13 April 2016 at 11:20am EDT in New York City.
SMMT: 6.78 (+0.03)

Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces positive interim data from a Phase 1 clinical trial evaluating a new oral formulation of its lead utrophin modulator, SMT C1100, for DMD. In this dose escalating clinical trial's initial dosing period, all patients achieved plasma drug levels within the range believed to be necessary for a potential therapeutic benefit. The initial dose tested of the new formulation was one tenth of that required with the current formulation of SMT C1100 to achieve similar drug concentration levels in the recent Phase 1b modified diet clinical trial of SMT C1100.
SMMT: 6.78 (+0.03)

Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole's Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
GlobeNewswire - Tue Mar 29, 8:25AM CDT
-- Data to be Presented at 26 ECCMID Conference, 11 April 2016
SMMT: 6.78 (+0.03)

Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
GlobeNewswire - Tue Mar 15, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces the online publication on the development of imaging techniques designed to quantify utrophin protein and muscle fibre regeneration in muscle biopsies from patients with DMD and Becker muscular dystrophy ('BMD'.
SMMT: 6.78 (+0.03)

Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
SMMT: 6.78 (+0.03)

Summit Financial Group Reports Fourth Quarter and Full Year 2015 Results
GlobeNewswire - Mon Jan 25, 5:00AM CST
Summit Financial Group, Inc. ("Company" or "Summit" (NASDAQ:SMMF) today reported fourth quarter 2015 net income applicable to common shares of $4.15 million, or $0.39 per diluted share, compared to $3.01 million, or $0.32 per diluted share, for the fourth quarter of 2014, representing an increase of 37.8 percent, or 21.9 percent per diluted share. Q4 2015 earnings compared to Q4 2014 were positively impacted by a $782,000 increase in net interest income and a $314,000 gain on sale of foreclosed properties, but were negatively impacted by a $336,000 increase in write-downs of foreclosed properties and a $250,000 provision for loan losses compared to zero for Q4 2014.
SMMF: 19.62 (-0.26)

Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
GlobeNewswire - Thu Jan 21, 6:11AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally administered, small molecule utrophin modulator that the Company believes has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. Utrophin is functionally and structurally similar to dystrophin, a protein which is essential for the healthy function of muscles.
SMMT: 6.78 (+0.03)

Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
GlobeNewswire - Tue Jan 19, 6:16AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces that the European Patent Office ('EPO' has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent having faced no challenge. The patent covers the use of ridinilazole for the treatment of infections caused by the bacterium Clostridium difficile.
SMMT: 6.78 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 22

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 126

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 51

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 5

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 18

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading

Top 5 Most Recently Viewed Articles

Fortune Brands' Strategic Moves for Growth and Innovation

Updated Category News Views 506

Fortune Brands Embraces Change for Future Growth Fortune Brands Innovations, Inc. (NYSE: FBIN), a leading innovation company committed to transforming spaces into havens, has announced pivotal changes aimed at enhancing its growth opportunities. These strategic moves reflect the company's dedication to innovation and efficiency as it positions itself for future success....

Continue Reading
Robert Webb's Insightful Stock Options Exercise at NHI

Updated Category News Views 97

Robert Webb Exercises Stock Options at National Health Investors Recently, an important SEC filing revealed that Robert Webb, a Board Member at National Health Investors (NHI), has exercised a significant number of stock options. Key Highlights: The latest Form 4 filing shows that Webb exercised stock options for 70,000 shares of NHI, amounting to a remarkable $1,585,550....

Continue Reading
Palantir Technologies Inc. Increases Investment in UK Defense

Updated Category News Views 271

Palantir Technologies Inc. Stock Update Recently, shares of Palantir Technologies Inc. (NASDAQ: PLTR) saw an increase of 1.58% in pre-market trading following the announcement of a substantial deal with the U.K. government. Strategic Investment in UK Defense This exciting new partnership involves Palantir committing up to £1.5 billion, equivalent to approximately $2...

Continue Reading
Investigation of Varonis Systems, Inc.: A Call to Investors

Updated Category News Views 165

Investigation into Varonis Systems, Inc. Edelson Lechtzin LLP, a well-respected national law firm, is actively investigating Varonis Systems, Inc. (NASDAQ: VRNS) due to potential violations of federal securities laws. This investigation arises from troubling allegations regarding the company's financial disclosures and communication with investors. Varonis Systems,...

Continue Reading
Error Notification on NAV Values in Wealth Invest Fund

Updated Category News Views 127

Error Notification Regarding NAV Values Nasdaq Copenhagen A/S Nikolaj Plads 6 1067 København K Important Information The latest update relates to incorrect NAV values published for the I&T Nordiske Aktier Large Cap division (ISIN: DK0061276656) of Investeringsforeningen Wealth Invest during a specific time frame. Details of the NAV Error This error occurred from 09:45 on...

Continue Reading